Skip to main content

Table 1 Demographics of patients with BM

From: The impact of neurological performance and volumetrics on overall survival in brain metastasis in colorectal cancer: a retrospective single-center case series

 

total CRC N = 25

colon cancer N = 11

rectal cancer N = 14

Number (%)

mean (min-max)

Number (%)

mean (min-max)

Number (%)

mean (min-max)

patient characteristics

 gender, female

6 (24.00)

 

5 (45.45)

 

1 (7.14)

 

 age at first diagnosis, yr

 

61.88 (30–81)

 

59.91 (30–81)

 

63.43 (51–78)

 age at first diagnosis, >  63 yr

10 (40.00)

 

4 (36.36)

 

6 (42.86)

 

 body mass index, kg/cm2

 

26.1 (19.1–41.6)

 

26.3 (19.1–41.6)

 

25.9 (22.0–32.4)

 high blood pressure

13 (52.00)

 

7 (63.64)

 

6 (42.86)

 

 alcohol consumption

2 (8.00)

 

0

 

2 (14.29)

 

 smoking history

2 (8.00)

 

1 (9.09)

 

1 (7.14)

 

 convulsion

6 (24.00)

 

1 (9.09)

 

5 (35.71)

 

 cardiovascular disease

7 (28.00)

 

4 (36.36)

 

3 (21.43)

 

 diabetes mellitus type II

4 (16.00)

 

4 (36.36)

 

0

 

 second malignoma

2 (8.00)

 

1 (9.09)

 

1 (7.14)

 

 chronic kidney injury

4 (16.00)

 

2 (18.18)

 

2 (14.29)

 

 chronic obstructive pulmonic disease

4 (16.00)

 

2 (18.18)

 

2 (14.29)

 

 cardiac stents

1 (4.00)

 

0

 

1 (7.14)

 

 adipositas

4 (16.00)

 

2 (18.18)

 

2 (14.29)

 

colorectal cancer

 UICC stage

n/a

2 (8.00)

 

0

 

2 (14.29)

 

I

3 (12.00)

 

1 (9.09)

 

2 (14.29)

 

II

1 (4.00)

 

1 (9.09)

 

0

 

III

10 (40.00)

 

6 (54.55)

 

4 (28.57)

 

IV

9 (36.00)

 

3 (27.27)

 

6 (42.86)

 

 Grading

n/a

2 (8.00)

 

1 (9.09)

 

1 (7.14)

 

G1

9 (36.00)

 

6 (54.55)

 

3 (21.43)

 

G2

8 (32.00)

 

3 (27.27)

 

5 (35.71)

 

G3

6 (24.00)

 

1 (9.09)

 

5 (35.71)

 

 pulmonary metastasis

18 (72.00)

 

7 (63.64)

 

11 (78.57)

 

 time from first diagnosis to pulmonary metastasis, mo

 

33.44 (0–103)

 

37.43 (0–82)

 

30.91 (0–703)

 liver metastasis

15 (60.00)

 

8 (72.73)

 

7 (50.00)

 

 time from first diagnosis to liver metastasis, mo

 

19.27 (0–98)

 

30.29 (0–98)

 

9.63 (0–40)

 other systemic metastasis (without brain)

9 (36.00)

 

3 (27.27)

 

6 (42.86)

 

 number chemotherapeutic drugs

 

3.08 (0–8)

 

3.64 (0–8)

 

2.64 (0–7)

 systemic chemotherapy

w/o

2 (8.00)

 

0

 

2 (14.29)

 

adjuvant

14 (56.00)

 

11 (100.00)

 

3 (21.43)

 

neoadjuvant + adjuvant

9 (36.00)

 

0

 

9 (64.29)

 

 systemic radiation therapy

w/o

14 (56.00)

 

8 (72.73)

 

6 (42.86)

 

neoadjuvant

4 (16.00)

 

0

 

4 (28.57)

 

adjuvant

7 (28.00)

 

3 (27.27)

 

4 (28.57)

 

brain metastasis

 age at diagnosis of BM, yr

 

65.80 (36–82)

 

64.27 (36–82)

 

67.00 (51–78)

 time from first diagnosis to BM, mo

 

47.16 (0–102)

 

52.91 (5–95)

 

42.64 (0–102)

 number of BMs

1

14 (56.00)

 

9 (81.82)

 

5 (35.71)

 

2

3 (12.00)

 

0

 

3 (21.43)

 

3

6 (24.00)

 

1 (9.09)

 

5 (35.71)

 

> 3

2 (8.00)

 

1 (9.09)

 

1 (7.14)

 

 localization of BM

cerebral

9 (36.00)

 

6 (54.55)

 

3 (21.43)

 

cerebellar

6 (24.00)

 

3 (27.27)

 

3 (21.43)

 

both

10 (40.00)

 

2 (18.18)

 

8 (57.14)

 

 symptoms of BM

incidental finding

4 (16.00)

 

3 (27.27)

 

1 (7.14)

 

unspecific CNS

3 (12.00)

 

3 (27.27)

 

0

 

specific CNS

18 (72.00)

 

5 (45.45)

 

13 (92.86)

 

 radiation therapy, brain

17 (68.00)

 

7 (63.64)

 

10 (71.43)

 

 radiation therapy, modality

stereotactic

11 (64.71)

 

5 (71.43)

 

6 (60.00)

 

whole brain

6 (35.29)

 

2 (28.57)

 

4 (40.00)

 

 radiation dose, Gy

 

38.31 (25–71)

 

33.50 (25–45)

 

41.20 (30–71)

surgery

 localization surgery

cerebral

11 (45.83)

 

6 (54.55)

 

5 (38.46)

 

cerebellar

13 (54.17)

 

5 (45.45)

 

8 (61.54)

 

 cross total resection

13 (54.17)

 

8 (72.73)

 

5 (38.46)

 

 age at death, yr

 

66.20 (37–81)

 

62.56 (37–81)

 

69.18 (51–79)

 time from first diagnosis to death, mo

 

51.75 (5–104)

 

56.44 (9–704)

 

47.91 (5–95)

 time from BM to death, mo

 

4.90 (0–18)

 

6 (0–18)

 

4 (0–9)

 time from BM to death, mo [median]

 

3.00 (0–18)

 

3 (0–18)

 

2 (0–9)

 six-month survival, mo

8 (40.00)

 

3 (33.33)

 

5 (45.45)

 

 one-year survival, mo

2 (10.00)

 

2 (22.22)

 

0

 
  1. BM brain metastasis, CI confidence interval, CRC colorectal cancer, CNS central nervous system, G grading, Gy Gray, HR Hazard ratio, KPS Karnofsky performance status, Mo months, MRC-NPS Medical Research Council Neurological Performance Ccore, N number, n/a not applicable, OS Overall survival, UICC Union for International Cancer Control, Yr years, w/o without